Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) in different experimental groups.

TAA treatment induced clear signs of hepatic failure with significant increases in plasma level of the LDH, accompanied by less dramatic but still significant increases in ALT and AST. The intranigral injection of DIOA (a KCC2 blocker, 20 µg/0.5 µl) did not affect any of the serum transaminases in normal mice. Similarly, the intranigral injection of bumetanide (BUM, a selective inhibitor of NKCC1, a 20 nmol/0.5 µl) could not alter the increases of plasma level of ALT and AST, while ameliorate LDH increase, in mice treated with TAA.
*p<0.05 as compared to normal controls;
#p<0.05 as compared to TAA group.